CABA
Price
$4.25
Change
-$0.21 (-4.71%)
Updated
Nov 12, 03:17 PM (EDT)
121 days until earnings call
IDYA
Price
$31.26
Change
-$0.72 (-2.25%)
Updated
Nov 12, 03:25 PM (EDT)
140 days until earnings call
Ad is loading...

CABA vs IDYA

Header iconCABA vs IDYA Comparison
Open Charts CABA vs IDYABanner chart's image
Cabaletta Bio
Price$4.25
Change-$0.21 (-4.71%)
Volume$950
CapitalizationN/A
IDEAYA Biosciences
Price$31.26
Change-$0.72 (-2.25%)
Volume$1.1K
CapitalizationN/A
CABA vs IDYA Comparison Chart
Loading...
CABA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CABA vs. IDYA commentary
Nov 12, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and IDYA is a StrongBuy.

COMPARISON
Comparison
Nov 12, 2024
Stock price -- (CABA: $4.46 vs. IDYA: $32.00)
Brand notoriety: CABA and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 79% vs. IDYA: 74%
Market capitalization -- CABA: $217.87M vs. IDYA: $2.77B
CABA [@Biotechnology] is valued at $217.87M. IDYA’s [@Biotechnology] market capitalization is $2.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $476.71B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 1 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CABA and IDYA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • CABA’s TA Score: 5 bullish, 2 bearish.
  • IDYA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CABA is a better buy in the short-term than IDYA.

Price Growth

CABA (@Biotechnology) experienced а +11.50% price change this week, while IDYA (@Biotechnology) price change was +6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.07%. For the same industry, the average monthly price growth was +12.75%, and the average quarterly price growth was +8.86%.

Reported Earning Dates

CABA is expected to report earnings on Mar 13, 2025.

IDYA is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (+2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.77B) has a higher market cap than CABA($218M). IDYA YTD gains are higher at: -10.062 vs. CABA (-80.352). CABA has higher annual earnings (EBITDA): -98.61M vs. IDYA (-187.16M). IDYA has more cash in the bank: 702M vs. CABA (203M). IDYA has less debt than CABA: IDYA (1.87M) vs CABA (7.4M). IDYA has higher revenues than CABA: IDYA (12M) vs CABA (0).
CABAIDYACABA / IDYA
Capitalization218M2.77B8%
EBITDA-98.61M-187.16M53%
Gain YTD-80.352-10.062799%
P/E RatioN/AN/A-
Revenue012M-
Total Cash203M702M29%
Total Debt7.4M1.87M396%
TECHNICAL ANALYSIS
Technical Analysis
CABAIDYA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 13 days ago
75%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
CABA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSDVX23.960.12
+0.50%
North Star Dividend I
MCRFX16.400.06
+0.37%
BlackRock Mid-Cap Value Investor C
SCWFX70.520.24
+0.34%
American Funds SMALLCAP World F1
FDESX41.620.03
+0.07%
Fidelity Advisor Diversified Stock O
BGPTX13.05-0.03
-0.21%
Baillie Gifford Developed EAFE All Cap 2

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with PLRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-0.67%
PLRX - CABA
38%
Loosely correlated
-3.13%
AUTL - CABA
35%
Loosely correlated
-5.90%
ENTO - CABA
35%
Loosely correlated
-7.49%
RCKT - CABA
35%
Loosely correlated
-3.50%
IDYA - CABA
35%
Loosely correlated
+2.30%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+2.30%
GRI - IDYA
54%
Loosely correlated
-2.86%
INAB - IDYA
47%
Loosely correlated
-1.08%
PLRX - IDYA
46%
Loosely correlated
-3.13%
ABSI - IDYA
44%
Loosely correlated
+5.41%
FATE - IDYA
44%
Loosely correlated
+6.20%
More